沃森生物：冻干带状疱疹病毒mRNA疫苗临床试验申请获得受理 全球尚无该技术路线疫苗上市

Core Viewpoint - Watson Bio's subsidiary has applied for clinical trials of a freeze-dried mRNA vaccine for herpes zoster, which has been accepted by the National Medical Products Administration [1] Company Summary - The mRNA vaccine is developed in collaboration with Blue Magpie Bio and Fudan University, utilizing an independently developed mRNA vaccine technology platform [1] - Currently, there are no mRNA-based herpes zoster vaccines available on the market, with existing options being live attenuated and recombinant vaccines [1] - The acceptance of the clinical trial application will not have a significant impact on the company's operating performance for the current year [1] Industry Summary - The development of mRNA vaccines represents a new technological approach in the vaccine industry, particularly for diseases like herpes zoster [1] - The absence of mRNA-based herpes zoster vaccines in the global market indicates a potential opportunity for innovation and market entry [1]